Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence (Q38305698)

2 September 2017

1 reference

title

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence (English)

1 reference

2 September 2017

A J Scheen

1

1 reference

PubMed ID

25554070

2 September 2017

N Paquot

series ordinal

2

1 reference

2 September 2017

1 December 2014

1 reference

2 September 2017

Diabetes and Metabolism

1 reference

2 September 2017

40

1 reference

2 September 2017

S4-S11

1 reference

2 September 2017

6 Suppl 1

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Glucolipotoxicity: fuel excess and beta-cell dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Dapagliflozin: glucuretic action and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Dapagliflozin: a review of its use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Ipragliflozin: first global approval

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

1 reference

7 January 2021

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972689-8

7 January 2021

10.1016/S1262-3636(14)72689-8

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25554070